Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...
June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...
DexCom DXCM recently announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System has received authorization from Health Canada for its use in adults aged 18 years and older living ...
Dexcom G7 15 Day is the longest‑lasting and most accurate 1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days 5. BURNABY, British ...
Medical Device Network on MSN
Health Canada authorises Dexcom G7 15 day CGM
The device demonstrates a MARD of 8% and includes a 12-hour grace period and mobile app compatibility.
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results